ALMR

Alamar Biosciences Inc

34.85

Sep 18 • 3:59 PM ET +2.84 (8.87%)

34.85

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Medical Devices USA Mid NASD

Today, 7:31 PMNo clear catalyst identified; ALMR's high-volume rally diverged from proteomics peers Friday

Peers: INMD IRTC GKOS BSX EW MDT TFX BAX BDX RMD

| Held by: ARKG IWM VTI VXF IWO VTWO SCHA IWN LFSC SCHB

Scroll to Statements

Index	RUT
Market Cap	2.42B
Enterprise Value	2.22B
Income	-
Sales	-
Book/sh	4.51
Cash/sh	3.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	222
IPO	Apr 17, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	7.73
P/C	9.67
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.23
Current Ratio	11.85
Debt/Eq	0.16
LT Debt/Eq	0.16
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-0.67
EPS next Q	-0.21
EPS this Y	-480.00%
EPS next Y	45.32%
EPS next 5Y	-21.86%
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 10 AMC
EPS/Sales Surpr.	28.55% 13.69%

Insider Own	48.32%
Insider Trans	1.42%
Inst Own	24.61%
Inst Trans	64.65%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.95%
SMA50	18.95%
SMA200	34.44%
Trades

Shs Outstand	69.39M
Shs Float	35.86M
Short Float	5.92%
Short Ratio	6.02
Short Interest	2.12M
52W High	38.54 -9.57%
52W Low	18.84 84.93%
Volatility	7.67% 6.73%
ATR (14)	2.40
RSI (14)	65.43
Beta	-
Rel Volume	5.76
Avg Volume	352.28K
Volume	2,027,665

Perf Week	24.96%
Perf Month	-1.94%
Perf Quarter	58.70%
Perf Half Y	-
Perf YTD	54.20%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.40
Target Price	33.40
Prev Close	32.01
Price	34.85
Change %	8.87%

Date	Action	Analyst	Rating Change	Price Target Change
May-12-26	Initiated	TD Cowen	Buy	$30
May-12-26	Initiated	Stifel	Buy	$28
May-12-26	Initiated	Leerink Partners	Outperform	$35
May-12-26	Initiated	JP Morgan	Overweight	$30
May-12-26	Initiated	BofA Securities	Neutral	$27

Sep-01-26 04:05PM	Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference (GlobeNewswire)
Aug-11-26 01:02AM	Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... (GuruFocus.com) +30.65%
Aug-10-26 04:38PM	Alamar: Q2 Earnings Snapshot (Associated Press)
04:05PM	Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance (GlobeNewswire)
04:03PM	Alamar Biosciences Expands Global Partnership with Alzheimer's Disease Data Initiative and Gates Ventures (GlobeNewswire)
08:05AM	Loading…
Aug-05-26 08:05AM	Attovia adds to biotech IPO momentum with $289M offering (BioPharma Dive)
Jul-28-26 04:12PM	Alamar Biosciences Launches NULISAseq Immune 340 Panel for Comprehensive Profiling of the Immune Proteome (GlobeNewswire)
Jul-15-26 07:34AM	Braveheart, Attovia join next wave of biotech IPOs (BioPharma Dive)
Jul-14-26 04:05PM	Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026 (GlobeNewswire)
Jul-13-26 04:50PM	Alamar Hits A High Note On Alzheimer's Buzz (Trefis)
02:30AM	Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases (GlobeNewswire)
Jul-10-26 06:11AM	Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer's Biomarker Profiling (GlobeNewswire) +7.33%
Jul-07-26 09:12AM	Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer's Disease Research (GlobeNewswire)
Jul-01-26 09:04AM	Cathie Wood Doubles Down on AI, Loads Up on Tesla, Palantir, and SpaceX (GuruFocus.com)
May-12-26 09:56AM	Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	Loading…
May-08-26 08:00AM	Alamar Biosciences Reports First Quarter 2026 Financial Results (GlobeNewswire)
May-05-26 04:05PM	Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference (GlobeNewswire)
Apr-19-26 10:41PM	Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ (PR Newswire)

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

Co-FounderDr. Yuling Luo Ph.D.

Co-FounderDr. Shiping Chen Ph.D.

Chief Financial OfficerMr. Justin J. McAnear

PresidentMr. Timothy Ogden White J.D.

Chief Technology OfficerDr. Xiao-Jun Ma Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Illumina Innovation Fund II GP	10% Owner	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:45 PM
Naclerio Nicholas	Director	Apr 20 '26	Buy	17.00	235,294	3,999,998	507,076	Apr 20 08:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALMR

Alamar Biosciences Inc

Upgrade your Finviz experience